A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis.
Latest Information Update: 09 Jul 2026
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SHINE
- Sponsors Swedish Orphan Biovitrum
Most Recent Events
- 30 Apr 2026 Planned End Date changed from 1 Dec 2026 to 28 Dec 2026.
- 30 Apr 2026 Planned primary completion date changed from 1 Dec 2026 to 17 Nov 2026.
- 19 Dec 2025 Status changed from recruiting to active, no longer recruiting.